Red Blood Cell-Hitchhiking Delivery of Simvastatin to Relieve Acute Respiratory Distress Syndrome

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Jun 11

PMID 38859953

Authors

Mengjuan Sun

Jun Wei

Yanhui Su

Yangjingwan He

Liang Ge

Yan Shen

Bohui Xu

Yanlong Bi

Chunli Zheng

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study is to address the high mortality and poor prognosis associated with Acute Respiratory Distress Syndrome (ARDS), conditions characterized by acute and progressive respiratory failure. The primary goal was to prolong drug circulation time, increase drug accumulation in the lungs, and minimize drug-related side effects.

Methods: Simvastatin (SIM) was used as the model drug in this study. Employing a red blood cell surface-loaded nanoparticle drug delivery technique, pH-responsive cationic nanoparticles loaded with SIM were non-covalently adsorbed onto the surface of red blood cells (RBC), creating a novel drug delivery system (RBC@SIM-PEI-PPNPs).

Results: The RBC@SIM-PEI-PPNPs delivery system effectively extended the drug's circulation time, providing an extended therapeutic window. Additionally, this method substantially improved the targeted accumulation of SIM in lung tissues, thereby enhancing the drug's efficacy in treating ARDS and impeding its progression to ARDS. Crucially, the system showed a reduced risk of adverse drug reactions.

Conclusion: RBC@SIM-PEI-PPNPs demonstrates promise in ARDS and ARDS treatment. This innovative approach successfully overcomes the limitations associated with SIM's poor solubility and low bioavailability, resulting in improved therapeutic outcomes and fewer drug-related side effects. This research holds significant clinical implications and highlights its potential for broader application in drug delivery and lung disease treatment.

References

Meyer N, Gattinoni L, Calfee C . Acute respiratory distress syndrome. Lancet. 2021; 398(10300):622-637. PMC: 8248927. DOI: 10.1016/S0140-6736(21)00439-6. View

Aikawa N, Ishizaka A, Hirasawa H, Shimazaki S, Yamamoto Y, Sugimoto H . Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. Pulm Pharmacol Ther. 2011; 24(5):549-54. DOI: 10.1016/j.pupt.2011.03.001. View

Rendell R, Fairhall S, Graham S, Rutter S, Auton P, Smith A . Assessment of N-acetylcysteine as a therapy for phosgene-induced acute lung injury. Toxicol Lett. 2018; 290:145-152. DOI: 10.1016/j.toxlet.2018.03.025. View

Zhang J, Huang X, Ding D, Zhang J, Xu L, Hu Z . Comparative Study of Acute Lung Injury in COVID-19 and Non-COVID-19 Patients. Front Med (Lausanne). 2021; 8:666629. PMC: 8415545. DOI: 10.3389/fmed.2021.666629. View

Altwairgi A . Statins are potential anticancerous agents (review). Oncol Rep. 2015; 33(3):1019-39. DOI: 10.3892/or.2015.3741. View

Deponte M . Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta. 2012; 1830(5):3217-66. DOI: 10.1016/j.bbagen.2012.09.018. View

Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler J . Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020; 8(3):267-276. DOI: 10.1016/S2213-2600(19)30417-5. View

Steinberg K, Hudson L, Goodman R, Hough C, Lanken P, Hyzy R . Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006; 354(16):1671-84. DOI: 10.1056/NEJMoa051693. View

Bao X, Mao A, Fang Y, Fan Y, Wang F, Ma J . Simvastatin decreases hyperbaric oxygen-induced acute lung injury by upregulating eNOS. Am J Physiol Lung Cell Mol Physiol. 2017; 314(2):L287-L297. DOI: 10.1152/ajplung.00520.2016. View

10.

Zeiher B, Artigas A, Vincent J, Dmitrienko A, Jackson K, Thompson B . Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004; 32(8):1695-702. DOI: 10.1097/01.ccm.0000133332.48386.85. View

11.

Slowing I, Wu C, Vivero-Escoto J, Lin V . Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. Small. 2008; 5(1):57-62. DOI: 10.1002/smll.200800926. View

12.

Antonelli A, Pacifico S, Sfara C, Tamma M, Magnani M . Ferucarbotran-loaded red blood cells as long circulating MRI contrast agents: first in vivo results in mice. Nanomedicine (Lond). 2018; 13(7):675-687. DOI: 10.2217/nnm-2017-0339. View

13.

Kellner M, Noonepalle S, Lu Q, Srivastava A, Zemskov E, Black S . ROS Signaling in the Pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). Adv Exp Med Biol. 2017; 967:105-137. PMC: 7120947. DOI: 10.1007/978-3-319-63245-2_8. View

14.

Choi J, Lee H, Seo K, Na J, Kim Y, Uh S . The effect of post-treatment N-acetylcysteine in LPS-induced acute lung injury of rats. Tuberc Respir Dis (Seoul). 2012; 73(1):22-31. PMC: 3475471. DOI: 10.4046/trd.2012.73.1.22. View

15.

Andreakos E, Papadaki M, Serhan C . Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19. Allergy. 2020; 76(3):626-628. PMC: 7537007. DOI: 10.1111/all.14595. View

16.

Antonelli A, Sfara C, Weber O, Pison U, Manuali E, Salamida S . Characterization of ferucarbotran-loaded RBCs as long circulating magnetic contrast agents. Nanomedicine (Lond). 2016; 11(21):2781-2795. DOI: 10.2217/nnm-2016-0216. View

17.

Lei J, Wang L, Zou L, Wang H, Zhang Y, Liu S . GDF3 Protects Mice against Sepsis-Induced Acute Lung Injury by Suppression of Macrophage Pyroptosis. Pharmaceuticals (Basel). 2024; 17(3). PMC: 10975191. DOI: 10.3390/ph17030268. View

18.

Chen J, Ma S, Luo B, Hao H, Li Y, Yang H . Human umbilical cord mesenchymal stromal cell small extracellular vesicle transfer of microRNA-223-3p to lung epithelial cells attenuates inflammation in acute lung injury in mice. J Nanobiotechnology. 2023; 21(1):295. PMC: 10464265. DOI: 10.1186/s12951-023-02038-3. View

19.

Bellani G, Laffey J, Pham T, Fan E, Brochard L, Esteban A . Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016; 315(8):788-800. DOI: 10.1001/jama.2016.0291. View

20.

Karabasz A, Szczepanowicz K, Cierniak A, Bereta J, Bzowska M . In vitro toxicity studies of biodegradable, polyelectrolyte nanocapsules. Int J Nanomedicine. 2018; 13:5159-5172. PMC: 6135212. DOI: 10.2147/IJN.S169120. View